Covaxin booster trial shows long-term safety

Six months following the second Covid treatment, 90% of those who received the booster dose exhibited a "detectable neutralising antibody response" against the wild-type strain, according to Bharat Biotech.

"Cell-mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous (Alpha, Beta, Delta, and Delta plus) strains persisted above baseline six months after a two-dose BBV152 vaccination series, though the magnitude of the responses had declined," the vaccine manufacturer said in a statement.

After a third vaccination, neutralising antibodies against homologous and heterologous SARS-CoV-2 variants rose 19 to 265-fold.
The vaccine maker stated, "Booster BBV152 immunisation is safe and may be required to establish durable protection to prevent breakthrough infections."

Also read: 4th Covid Booster Enhances Antibodies

Bharat Biotech's Chairman and Managing Director, Krishna Ella, stated, "These findings lay a solid foundation for our aim of providing Covaxin as a booster dosage. Our aim of establishing a universal Covid-19 vaccination has been accomplished. Adults, children, and 2-dose initial and booster doses of Covaxin are now recommended. As a result, Covaxin can be used as a universal vaccination."

Bharat Biotech feels that a third dosage may be advantageous to maintain the maximum levels of protection, based on developing research, he added. (IANS/PR)

(Keywords: Covaxin booster, Bharat Biotech's Chairman and Managing Director, Krishna Ella, Bharat Biotech, Booster BBV152)